The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol.
Thijssen
H H
HH
Department of Pharmacology, University of Maastricht, The Netherlands. h.thijssen@farmaco.unimaas.nl
Verkooijen
I W
IW
Frank
H L
HL
D000074:Acenocoumarol / Q000627:therapeutic use*; D000368:Aged; D000483:Alleles; D000925:Anticoagulants / Q000627:therapeutic use*; D001189:Aryl Hydrocarbon Hydroxylases; D065731:Cytochrome P-450 CYP2C19; D065729:Cytochrome P-450 CYP2C9; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D006899:Mixed Function Oxygenases / Q000235:genetics; D039181:Steroid 16-alpha-Hydroxylase; D013250:Steroid Hydroxylases / Q000235:genetics*
D000925:Anticoagulants; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; D013250:Steroid Hydroxylases; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D039181:Steroid 16-alpha-Hydroxylase; D000074:Acenocoumarol